Skip to main content
Equibles
TNGX logo

TNGX · Tango Therapeutics, Inc. · Metrics

Track TNGX — free

Use TNGX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TNGX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$23.78 +0.41 (+1.75%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$4.01B
Shares
168.61M

TNGX metrics

59 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$23.78
Market cap
$3.94B

Price action

20 metrics
Price change (1W)
+2.7%
Price change (30D)
-8.9%
Price change (3M)
-21.6%
Price change (6M)
+36.3%
Price change (YTD)
+163.8%
Price change (1Y)
+267.5%
Trailing year
Price change (5Y)
+49.9%
52-week high
$32.90
52-week low
$6.36
Change from 52-week high
-29.0%
Change from 52-week low
+267.5%
Annualized volatility
101.1%
Annualized volatility (3M)
64.9%
Beta
1.5
RSI (14D)
42.7
Price vs SMA 50
-12.1%
Price vs SMA 200
+17.9%
Avg volume (3M)
3.23M
Relative volume
1.1
Average dollar volume
$91.26M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
168.61M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
73.1×
reciprocal yield 1.4%
P / book
3.8
reciprocal yield 26.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-3.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-253.4%
Trailing 12 months
Net margin
-229.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$136.35M
Net income (TTM)
−$123.72M
Trailing 12 months
Diluted EPS (TTM)
$-0.85
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.55

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$53.81M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+35.6%
Year over year · more shares
Revenue CAGR (3Y)
+35.9%
Revenue CAGR (5Y)
+52.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-12.1%
Return on assets
-11.5%
Debt / equity
—
Current ratio
50.8
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
50.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.01B
Latest balance sheet
Cash & equivalents
$345.56M
Total assets
$1.07B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$143.90M
Capital expenditures (TTM)
$351,000
R&D (TTM)
$133.65M
SG&A (TTM)
—
Stock compensation (TTM)
$40.29M
R&D / revenue
248.4%
Stock compensation / revenue
74.9%

Ownership (13F)

3 metrics
13F filers
249
13F filer change QoQ
+54
Institutional ownership
127.2%

Short interest

3 metrics
Short interest
25.3%
Latest settlement · 19.7 days to cover
Days to cover
19.7d
Short-squeeze score
74 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$2.14M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1819133 CUSIP 87583X109 13F (30d) 147 filings 147 filers Visit website Investor relations